Comparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension: Results of 24-hour ambulatory blood pressure monitoring

Maurizio Destro, Rossana Scabrosetti, Alessandro Vanasia, Amedeo Mugellini

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The aim of this prospective, randomized, open-label, blinded endpoint (PROBE) study was to compare the antihypertensive efficacy of 2 angiotensin II (AII) receptor antagonists with different pharmacologic profiles, valsartan and olmesartan, in patients with mild-to-moderate essential hypertension. After an initial 2-week washout period, 114 patients (64 men, 50 women; aged 35-70 years) were randomly assigned to receive valsartan 160 mg or olmesartan 20 mg once daily for 8 weeks. After the washout period and after 2 and 8 weeks of treatment, 24-hour ambulatory blood pressure monitoring (ABPM) was performed using a noninvasive device, and casual blood pressure (BP) and heart rate were measured. Both olmesartan and valsartan had a clear-cut antihypertensive effect. However, significantly earlier and more pronounced antihypertensive activity was achieved with valsartan than with olmesartan, as demonstrated by (1) significantly lower 24-hour, daytime, and nighttime ABPM values after 2 weeks with valsartan (P

Original languageEnglish
Pages (from-to)32-43
Number of pages12
JournalAdvances in Therapy
Volume22
Issue number1
Publication statusPublished - Jan 2005

Fingerprint

Valsartan
Ambulatory Blood Pressure Monitoring
Hypertension
Antihypertensive Agents
Angiotensin Receptor Antagonists
Heart Rate
olmesartan
Blood Pressure
Equipment and Supplies

Keywords

  • Ambulatory blood pressure monitoring
  • Hypertension
  • Olmesartan
  • Valsartan

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Comparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension : Results of 24-hour ambulatory blood pressure monitoring. / Destro, Maurizio; Scabrosetti, Rossana; Vanasia, Alessandro; Mugellini, Amedeo.

In: Advances in Therapy, Vol. 22, No. 1, 01.2005, p. 32-43.

Research output: Contribution to journalArticle

@article{c40b6074857a493c9883be6071dfa39b,
title = "Comparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension: Results of 24-hour ambulatory blood pressure monitoring",
abstract = "The aim of this prospective, randomized, open-label, blinded endpoint (PROBE) study was to compare the antihypertensive efficacy of 2 angiotensin II (AII) receptor antagonists with different pharmacologic profiles, valsartan and olmesartan, in patients with mild-to-moderate essential hypertension. After an initial 2-week washout period, 114 patients (64 men, 50 women; aged 35-70 years) were randomly assigned to receive valsartan 160 mg or olmesartan 20 mg once daily for 8 weeks. After the washout period and after 2 and 8 weeks of treatment, 24-hour ambulatory blood pressure monitoring (ABPM) was performed using a noninvasive device, and casual blood pressure (BP) and heart rate were measured. Both olmesartan and valsartan had a clear-cut antihypertensive effect. However, significantly earlier and more pronounced antihypertensive activity was achieved with valsartan than with olmesartan, as demonstrated by (1) significantly lower 24-hour, daytime, and nighttime ABPM values after 2 weeks with valsartan (P",
keywords = "Ambulatory blood pressure monitoring, Hypertension, Olmesartan, Valsartan",
author = "Maurizio Destro and Rossana Scabrosetti and Alessandro Vanasia and Amedeo Mugellini",
year = "2005",
month = "1",
language = "English",
volume = "22",
pages = "32--43",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Springer Healthcare",
number = "1",

}

TY - JOUR

T1 - Comparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension

T2 - Results of 24-hour ambulatory blood pressure monitoring

AU - Destro, Maurizio

AU - Scabrosetti, Rossana

AU - Vanasia, Alessandro

AU - Mugellini, Amedeo

PY - 2005/1

Y1 - 2005/1

N2 - The aim of this prospective, randomized, open-label, blinded endpoint (PROBE) study was to compare the antihypertensive efficacy of 2 angiotensin II (AII) receptor antagonists with different pharmacologic profiles, valsartan and olmesartan, in patients with mild-to-moderate essential hypertension. After an initial 2-week washout period, 114 patients (64 men, 50 women; aged 35-70 years) were randomly assigned to receive valsartan 160 mg or olmesartan 20 mg once daily for 8 weeks. After the washout period and after 2 and 8 weeks of treatment, 24-hour ambulatory blood pressure monitoring (ABPM) was performed using a noninvasive device, and casual blood pressure (BP) and heart rate were measured. Both olmesartan and valsartan had a clear-cut antihypertensive effect. However, significantly earlier and more pronounced antihypertensive activity was achieved with valsartan than with olmesartan, as demonstrated by (1) significantly lower 24-hour, daytime, and nighttime ABPM values after 2 weeks with valsartan (P

AB - The aim of this prospective, randomized, open-label, blinded endpoint (PROBE) study was to compare the antihypertensive efficacy of 2 angiotensin II (AII) receptor antagonists with different pharmacologic profiles, valsartan and olmesartan, in patients with mild-to-moderate essential hypertension. After an initial 2-week washout period, 114 patients (64 men, 50 women; aged 35-70 years) were randomly assigned to receive valsartan 160 mg or olmesartan 20 mg once daily for 8 weeks. After the washout period and after 2 and 8 weeks of treatment, 24-hour ambulatory blood pressure monitoring (ABPM) was performed using a noninvasive device, and casual blood pressure (BP) and heart rate were measured. Both olmesartan and valsartan had a clear-cut antihypertensive effect. However, significantly earlier and more pronounced antihypertensive activity was achieved with valsartan than with olmesartan, as demonstrated by (1) significantly lower 24-hour, daytime, and nighttime ABPM values after 2 weeks with valsartan (P

KW - Ambulatory blood pressure monitoring

KW - Hypertension

KW - Olmesartan

KW - Valsartan

UR - http://www.scopus.com/inward/record.url?scp=18444416063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18444416063&partnerID=8YFLogxK

M3 - Article

C2 - 15943220

AN - SCOPUS:18444416063

VL - 22

SP - 32

EP - 43

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

IS - 1

ER -